ReviewDigestive diseases and sciences2015
Cell mediators of autoimmune hepatitis and their therapeutic implications.
Review in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Pathogenesis, Non-Invasive Assessments and Treatment of Hepatic Fibrosis in Autoimmune Liver Diseases.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.Digestive diseases and sciences · 2022Review
- Targeting Glutamine Metabolism Ameliorates Autoimmune HepatitisFrontiers in immunology · 2022Article
- Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.Digestive diseases and sciences · 2021Review
- Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease.World journal of gastroenterology · 2021Review
- Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions.World journal of gastroenterology · 2019Review
- [Supportive therapy and management of side effects in dermato-oncology].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Article
- Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis.Digestive diseases and sciences · 2019Review
- Article
- Methylprednisolone Decreases Mitochondria-Mediated Apoptosis and Autophagy Dysfunction in Hepatocytes of Experimental Autoimmune Hepatitis ModelFrontiers in pharmacology · 2019Article
- Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.Digestive diseases and sciences · 2018Review
- Increased Expression of Aryl Hydrocarbon Receptor in Peripheral Blood Mononuclear Cells of Patients with Autoimmune Hepatitis.Middle East journal of digestive diseases · 2018Article
- Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis.Digestive diseases and sciences · 2017Observational
- Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases.Journal of immunology research · 2017Article
- Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis.World journal of gastroenterology · 2016Review
- Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Digestive diseases and sciences · 2016Review
- Adaptive immunity in the liver.Cellular & molecular immunology · 2016Review
- Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.Gut and liver · 2016Review
- Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.Digestive diseases and sciences · 2015Review
- Patients with treated autoimmune hepatitis and persistent suppression of plasmacytoid dendritic cells: A different point of view.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hepatitis is associated with interactive cell populations of the innate and adaptive immune systems, and these populations are amenable to therapeutic manipulation. The goals of this review are to describe the key cell populations implicated in autoimmune hepatitis and to identify investigational opportunities to develop cell-directed therapies for this disease. Studies cited in PubMed from 1972 to 2014 for autoimmune hepatitis, innate and adaptive immune systems, and therapeutic interventions were examined. Dendritic cells can promote immune tolerance to self-antigens, present neo-antigens that enhance the immune response, and expand the regulatory T cell population. Natural killer cells can secrete pro-inflammatory and anti-inflammatory cytokines and modulate the activity of dendritic cells and antigen-specific T lymphocytes. T helper 2 lymphocytes can inhibit the cytotoxic activities of T helper 1 lymphocytes and limit the expansion of T helper 17 lymphocytes. T helper 17 lymphocytes can promote inflammatory activity, and they can also up-regulate genes that protect against oxidative stress and hepatocyte apoptosis. Natural killer T cells can expand the regulatory T cell population; gamma delta lymphocytes can secrete interleukin-10, stimulate hepatic regeneration, and induce the apoptosis of hepatic stellate cells; and antigen-specific regulatory T cells can dampen immune cell proliferation and function. Pharmacological agents, neutralizing antibodies, and especially the adoptive transfer of antigen-specific regulatory T cells that have been freshly generated ex vivo are evolving as management strategies. The cells within the innate and adaptive immune systems are key contributors to the occurrence of autoimmune hepatitis, and they are attractive therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.